Select Page

P. HILLMANN,2 D. RAGEOT3, F. B. ILS2, P. HEBEISEN2, J.B. LANGLOIS3, C. BORSARI3, S. LEISER1, S. L. ROBERDS4, W. LOSCHER5, M. P. WYMANN3, D. FABBRO2


1PsychoGenics, Inc., Paramus, NJ, USA; 2PIQUR Therapeutics, Basel, Switzerland; 3Department of Biomedicine, Basel, Switzerland; 4TS Alliance, Silver Spring, MD, USA; 5University of Veterinary Medicine, Hannover, Germany.


Seizures are observed in 80 -90 % of TSC patients and are one of the disease manifestations that have the biggest impact on patients’ quality of life. Two ATP-competitive inhibitors of the mTOR pathway have been evaluated for their potential to reduce seizures and to extend life span in the Tsc1flox/flox-GFAP-Cre (TSC – GFAP [glial fibrillary acidic protein]) mouse model of TSC- induced epilepsy. POR530 is a potent, selective dual Pl31